Medicare Competitive Bidding Makes Big Impression On U.S. Diabetes Device Earnings
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson and Abbott Laboratories each reported massive double-digit revenue drops for their U.S. diabetes product divisions in earnings reports this week, citing the impact of the national Medicare competitive bidding program for diabetes supplies. Roche had better-looking results for the most recent quarter, but also has taken a big hit from massive reimbursement cuts resulting from nationwide bidding.
You may also be interested in...
Abbott Earns CE Mark For FreeStyle Libre Bloodless Glucose Monitor
FreeStyle Libre reads glucose levels through a interstitial fluid sensor on the back of the patient’s arm, but unlike current continuous glucose monitors does not require finger-stick calibrations.
Medicare Durable Equipment Cuts Will Deepen In Next Round Of Competitive Bidding
Starting July 1, Medicare plans to pay 45 percent less than current fee-schedule rates for eight categories of DMEPOS in 91 cities, and 72 percent less nationwide for diabetes products.
Huma Secures EU MDR Approval For Medtech Software That Can Be Used In Any Disease
Huma Therapeutics has secured the first ever EU regulatory approval for a “disease agnostic” class IIb medtech software platform. CEO Dan Vahdat tells Medtech Insight how the product can be configured to monitor patients with any condition.